XELOX III. Xeloda in Combination With Eloxatin for Patients With Advanced or Metastatic Colorectal Cancer

Inclusion Criteria: * Histological proven adenocarcinoma of the colon or rectum * Measurable or non-measurable disease * Performance status 0-2 * Adequate renal and hepatic functions * Adjuvant chemotherapy must have ended 180 days before inclusion * Written informed consent prior to randomization Exclusion Criteria: * Prior treatment with Eloxatin or Xeloda * Peripheral neuropathy * Evidence of CNS metastasis * Other serious illness or medical conditions (including contraindication to 5 FU e.g.: angor, myocardial infarction within 6 months) * Past history of malignant neoplasm within the past five years, except curatively treated non melanoma skin cancer * Administration of any other experimental drug under investigation within 2 weeks before randomisation * Pregnant or breast feeding women * Fertile patients must use adequate contraceptives